A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing VISIONARY study.

In the first 320 trial participants randomized in the phase III study, those treated with sibeprenlimab achieved a 50.2% reduction in proteinuria measured by 24-hour urine protein-to-creatinine ratio (uPCR) after 9 months compared with a 2.1% increase in the placebo group (placebo-adjusted treatment effect 51.2%, 96.5% CI 42.9-58.2%, P <0.0001), said Vlado Perkovic, MD, PhD, of the University of New South Wales in Sydney.

"This is the largest numerical effect [in proteinuria reduction] observed to date in any of the phase III [IgAN] trials that were reported so far," Perkovic said at the European Renal Association (ERA) annual congress. Proteinur

See Full Page